Lundbeck looking to fill gap left by gaboxadol

Faced with the failure of its sleep aid gaboxadol last week, analysts expect Denmark's H. Lundbeck to mount an aggressive licensing program or look at mergers and acquisitions to boost its business. The problem, they say, is that Lundbeck doesn't have the U.S. presence needed to make many in-licensing deals attractive and drug candidates have become so hotly sought after that few deals are available. Another factor, analysts tell The Wall Street Journal, is that Lundbeck focuses on the central nervous system, which severely restricts the types of licensing deals it can do.

Gaboxadol--being developed with Merck--was supposed to be Lundbeck's entrée into the U.S. and a successor to Lexapro, which loses its U.S. patent in 2012. The experimental antidepressant lu AA21004, meanwhile, is only in Phase II trials. A stroke drug and the antipsychotic Bifeprunox are both in Phase III, but each of those trials carries significant risk of failure. Lundbeck, though, says it has enough cash on hand to acquire another company of its own size, if it decides it needs to.

- read The Wall Street Journal article on Lundbeck (sub. req.)

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.